These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

174 related items for PubMed ID: 22814222

  • 21. Nebulization of four commercially available amphotericin B formulations in persistently granulocytopenic rats with invasive pulmonary aspergillosis: evidence for long-term biological activity.
    Ruijgrok EJ, Fens MH, Bakker-Woudenberg IA, van Etten EW, Vulto AG.
    J Pharm Pharmacol; 2005 Oct; 57(10):1289-95. PubMed ID: 16259757
    [Abstract] [Full Text] [Related]

  • 22. Synthesis and evaluation of sodium deoxycholate sulfate as a lipid drug carrier to enhance the solubility, stability and safety of an amphotericin B inhalation formulation.
    Gangadhar KN, Adhikari K, Srichana T.
    Int J Pharm; 2014 Aug 25; 471(1-2):430-8. PubMed ID: 24907597
    [Abstract] [Full Text] [Related]

  • 23. Nebulized liposomal amphotericin B prophylaxis for Aspergillus infection in lung transplantation: pharmacokinetics and safety.
    Monforte V, Ussetti P, López R, Gavaldà J, Bravo C, de Pablo A, Pou L, Pahissa A, Morell F, Román A.
    J Heart Lung Transplant; 2009 Feb 25; 28(2):170-5. PubMed ID: 19201343
    [Abstract] [Full Text] [Related]

  • 24. Aerosolised liposomal amphotericin B to prevent aspergillosis in acute myeloid leukaemia: Efficacy and cost effectiveness in real-life.
    Chong GL, Broekman F, Polinder S, Doorduijn JK, Lugtenburg PJ, Verbon A, Cornelissen JJ, Rijnders BJ.
    Int J Antimicrob Agents; 2015 Jul 25; 46(1):82-7. PubMed ID: 25956843
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. The novel lipid delivery system of amphotericin B: drug profile and relevance to clinical practice.
    Rust DM, Jameson G.
    Oncol Nurs Forum; 1998 Jul 25; 25(1):35-48. PubMed ID: 9460772
    [Abstract] [Full Text] [Related]

  • 27. Sequential or combination antifungal therapy with voriconazole and liposomal amphotericin B in a Guinea pig model of invasive aspergillosis.
    Kirkpatrick WR, Coco BJ, Patterson TF.
    Antimicrob Agents Chemother; 2006 Apr 25; 50(4):1567-9. PubMed ID: 16569887
    [Abstract] [Full Text] [Related]

  • 28. Liposomal amphotericin B dry powder inhaler: effect of fines on in vitro performance.
    Shah SP, Misra A.
    Pharmazie; 2004 Oct 25; 59(10):812-3. PubMed ID: 15544064
    [Abstract] [Full Text] [Related]

  • 29. Comparison between concentrations of amphotericin B in infected lung lesion and in uninfected lung tissue in a patient treated with liposomal amphotericin B (AmBisome).
    Watanabe A, Matsumoto K, Igari H, Uesato M, Yoshida S, Nakamura Y, Morita K, Shibuya K, Matsubara H, Yoshino I, Kamei K.
    Int J Infect Dis; 2010 Sep 25; 14 Suppl 3():e220-3. PubMed ID: 19959388
    [Abstract] [Full Text] [Related]

  • 30. Prophylaxis with nebulized liposomal amphotericin B for Aspergillus infection in lung transplant patients does not cause changes in the lipid content of pulmonary surfactant.
    Monforte V, López-Sánchez A, Zurbano F, Ussetti P, Solé A, Casals C, Cifrian J, de Pablos A, Bravo C, Román A.
    J Heart Lung Transplant; 2013 Mar 25; 32(3):313-9. PubMed ID: 23332731
    [Abstract] [Full Text] [Related]

  • 31. High-dose induction liposomal amphotericin B followed by de-escalation is effective in experimental Aspergillus terreus pneumonia.
    Lewis RE, Albert NP, Liao G, Wang W, Prince RA, Kontoyiannis DP.
    J Antimicrob Chemother; 2013 May 25; 68(5):1148-51. PubMed ID: 23349440
    [Abstract] [Full Text] [Related]

  • 32. Interactions of free and liposomal amphotericin B with renal proximal tubular cells in primary culture.
    Joly V, Saint-Julien L, Carbon C, Yeni P.
    J Pharmacol Exp Ther; 1990 Oct 25; 255(1):17-22. PubMed ID: 2213553
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Pharmacokinetics characterization of liposomal amphotericin B: investigation of clearance process and drug interaction potential.
    Matsui S, Imai S, Yabuki M, Komuro S.
    Arzneimittelforschung; 2009 Oct 25; 59(9):461-70. PubMed ID: 19856794
    [Abstract] [Full Text] [Related]

  • 35. Efficacy of alternative dosing regimens of poly-aggregated amphotericin B.
    Espada R, Valdespina S, Molero G, Dea MA, Ballesteros MP, Torrado JJ.
    Int J Antimicrob Agents; 2008 Jul 25; 32(1):55-61. PubMed ID: 18534826
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial.
    Rijnders BJ, Cornelissen JJ, Slobbe L, Becker MJ, Doorduijn JK, Hop WC, Ruijgrok EJ, Löwenberg B, Vulto A, Lugtenburg PJ, de Marie S.
    Clin Infect Dis; 2008 May 01; 46(9):1401-8. PubMed ID: 18419443
    [Abstract] [Full Text] [Related]

  • 38. Water-soluble amphotericin B-polyvinylpyrrolidone complexes with maintained antifungal activity against Candida spp. and Aspergillus spp. and reduced haemolytic and cytotoxic effects.
    Charvalos E, Tzatzarakis MN, Van Bambeke F, Tulkens PM, Tsatsakis AM, Tzanakakis GN, Mingeot-Leclercq MP.
    J Antimicrob Chemother; 2006 Feb 01; 57(2):236-44. PubMed ID: 16361329
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Amphotericin B lipid complex versus liposomal amphotericin B monotherapy for invasive aspergillosis in patients with hematologic malignancy.
    Hachem RY, Boktour MR, Hanna HA, Husni RN, Torres HA, Afif C, Kontoyiannis DP, Raad II.
    Cancer; 2008 Mar 15; 112(6):1282-7. PubMed ID: 18224662
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.